Premium
Endothelin Inhibition Potentiates Cancer Immunotherapy Revealing Mechanical Biomarkers Predictive of Response (Adv. Therap. 9/2021)
Author(s) -
Voutouri Chrysovalantis,
Panagi Myrofora,
Mpekris Fotios,
Stylianou Andreas,
Michael Christina,
Averkiou Michalakis A.,
Martin John D.,
Stylianopoulos Triantafyllos
Publication year - 2021
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.202170021
Subject(s) - bosentan , immunotherapy , tumor microenvironment , medicine , cancer research , endothelin 1 , endothelin receptor , cancer immunotherapy , immune system , pathology , receptor , immunology , tumor cells
Bosentan, an endothelin‐receptor blocker, can both normalize the tumor microenvironment, reprograming fibroblasts and reducing collagen thereby decompressing tumor blood vessels, and also increase T cell adhesion to the tumor vasculature. Together these effects significantly improve the efficacy of immune checkpoint inhibition. In addition, mechanical biomarkers derived from ultrasound elastography can predict the tumor response to immunotherapy. This is reported by John D. Martin, Triantafyllos Stylianopoulos, and co‐workers in article number 2000289.